vs
Side-by-side financial comparison of BWX Technologies, Inc. (BWXT) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $885.8M, roughly 1.7× BWX Technologies, Inc.). BWX Technologies, Inc. runs the higher net margin — 10.5% vs 4.4%, a 6.1% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 18.7%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $56.8M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 21.1%).
BWX Technologies, Inc. is a company headquartered in Lynchburg, Virginia that supplies nuclear components and fuel internationally.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
BWXT vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $885.8M | $1.5B |
| Net Profit | $93.0M | $66.5M |
| Gross Margin | — | 90.5% |
| Operating Margin | 10.4% | 12.4% |
| Net Margin | 10.5% | 4.4% |
| Revenue YoY | 18.7% | 32.8% |
| Net Profit YoY | 30.9% | 143.8% |
| EPS (diluted) | $1.02 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $885.8M | $1.5B | ||
| Q3 25 | $866.3M | $1.4B | ||
| Q2 25 | $764.0M | $1.3B | ||
| Q1 25 | $682.3M | $1.1B | ||
| Q4 24 | $746.3M | $1.1B | ||
| Q3 24 | $672.0M | $1.0B | ||
| Q2 24 | $681.5M | $929.2M | ||
| Q1 24 | $604.0M | $751.7M |
| Q4 25 | $93.0M | $66.5M | ||
| Q3 25 | $82.1M | $124.8M | ||
| Q2 25 | $78.4M | $94.3M | ||
| Q1 25 | $75.5M | $1.3M | ||
| Q4 24 | $71.0M | $-151.9M | ||
| Q3 24 | $69.5M | $-121.3M | ||
| Q2 24 | $73.0M | $-120.4M | ||
| Q1 24 | $68.5M | $-251.2M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | 21.8% | 86.1% | ||
| Q2 25 | 25.1% | 87.5% | ||
| Q1 25 | 24.2% | 85.2% | ||
| Q4 24 | — | 85.8% | ||
| Q3 24 | 24.4% | 83.0% | ||
| Q2 24 | 24.7% | 85.1% | ||
| Q1 24 | 24.6% | 83.4% |
| Q4 25 | 10.4% | 12.4% | ||
| Q3 25 | 13.1% | 11.5% | ||
| Q2 25 | 13.4% | 6.7% | ||
| Q1 25 | 14.2% | 1.0% | ||
| Q4 24 | 12.4% | -7.0% | ||
| Q3 24 | 14.4% | -12.0% | ||
| Q2 24 | 14.5% | -11.5% | ||
| Q1 24 | 15.4% | -34.8% |
| Q4 25 | 10.5% | 4.4% | ||
| Q3 25 | 9.5% | 8.8% | ||
| Q2 25 | 10.3% | 7.2% | ||
| Q1 25 | 11.1% | 0.1% | ||
| Q4 24 | 9.5% | -13.5% | ||
| Q3 24 | 10.3% | -12.1% | ||
| Q2 24 | 10.7% | -13.0% | ||
| Q1 24 | 11.3% | -33.4% |
| Q4 25 | $1.02 | $0.05 | ||
| Q3 25 | $0.89 | $0.08 | ||
| Q2 25 | $0.85 | $0.06 | ||
| Q1 25 | $0.82 | $0.00 | ||
| Q4 24 | $0.77 | $-0.10 | ||
| Q3 24 | $0.76 | $-0.09 | ||
| Q2 24 | $0.79 | $-0.09 | ||
| Q1 24 | $0.75 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $499.8M | $4.5B |
| Total DebtLower is stronger | — | $836.4M |
| Stockholders' EquityBook value | $1.2B | $4.4B |
| Total Assets | $4.3B | $8.2B |
| Debt / EquityLower = less leverage | — | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $499.8M | $4.5B | ||
| Q3 25 | $79.6M | $4.0B | ||
| Q2 25 | $37.0M | $2.8B | ||
| Q1 25 | $55.4M | $2.5B | ||
| Q4 24 | $74.1M | $2.6B | ||
| Q3 24 | $35.5M | $2.7B | ||
| Q2 24 | $48.3M | $2.6B | ||
| Q1 24 | $45.9M | $2.8B |
| Q4 25 | — | $836.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $4.4B | ||
| Q3 25 | $1.2B | $4.1B | ||
| Q2 25 | $1.2B | $3.8B | ||
| Q1 25 | $1.1B | $3.5B | ||
| Q4 24 | $1.1B | $3.3B | ||
| Q3 24 | $1.1B | $3.4B | ||
| Q2 24 | $998.5M | $3.4B | ||
| Q1 24 | $946.2M | $3.4B |
| Q4 25 | $4.3B | $8.2B | ||
| Q3 25 | $3.8B | $7.6B | ||
| Q2 25 | $3.7B | $6.3B | ||
| Q1 25 | $3.1B | $5.8B | ||
| Q4 24 | $2.9B | $5.9B | ||
| Q3 24 | $2.9B | $5.8B | ||
| Q2 24 | $2.8B | $5.7B | ||
| Q1 24 | $2.8B | $5.7B |
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $127.0M | $417.3M |
| Free Cash FlowOCF − Capex | $56.8M | $379.8M |
| FCF MarginFCF / Revenue | 6.4% | 25.4% |
| Capex IntensityCapex / Revenue | 7.9% | 2.5% |
| Cash ConversionOCF / Net Profit | 1.37× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $295.3M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $127.0M | $417.3M | ||
| Q3 25 | $143.2M | $402.6M | ||
| Q2 25 | $159.0M | $263.6M | ||
| Q1 25 | $50.6M | $44.1M | ||
| Q4 24 | $276.9M | $75.2M | ||
| Q3 24 | $32.6M | $188.4M | ||
| Q2 24 | $65.9M | $-95.6M | ||
| Q1 24 | $33.0M | $-308.6M |
| Q4 25 | $56.8M | $379.8M | ||
| Q3 25 | $94.9M | $354.5M | ||
| Q2 25 | $126.3M | $219.8M | ||
| Q1 25 | $17.3M | $-12.3M | ||
| Q4 24 | $224.4M | $-17.3M | ||
| Q3 24 | $-7.7M | $54.7M | ||
| Q2 24 | $35.5M | $-205.5M | ||
| Q1 24 | $2.6M | $-465.1M |
| Q4 25 | 6.4% | 25.4% | ||
| Q3 25 | 11.0% | 25.1% | ||
| Q2 25 | 16.5% | 16.7% | ||
| Q1 25 | 2.5% | -1.1% | ||
| Q4 24 | 30.1% | -1.5% | ||
| Q3 24 | -1.1% | 5.5% | ||
| Q2 24 | 5.2% | -22.1% | ||
| Q1 24 | 0.4% | -61.9% |
| Q4 25 | 7.9% | 2.5% | ||
| Q3 25 | 5.6% | 3.4% | ||
| Q2 25 | 4.3% | 3.3% | ||
| Q1 25 | 4.9% | 5.0% | ||
| Q4 24 | 7.0% | 8.2% | ||
| Q3 24 | 6.0% | 13.3% | ||
| Q2 24 | 4.5% | 11.8% | ||
| Q1 24 | 5.0% | 20.8% |
| Q4 25 | 1.37× | 6.28× | ||
| Q3 25 | 1.74× | 3.22× | ||
| Q2 25 | 2.03× | 2.79× | ||
| Q1 25 | 0.67× | 34.71× | ||
| Q4 24 | 3.90× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.90× | — | ||
| Q1 24 | 0.48× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BWXT
| Nuclear Component Program | $436.4M | 49% |
| Nuclear Manufacturing | $134.8M | 15% |
| Cost Plus Fee | $116.1M | 13% |
| Uranium And Nuclear Services | $103.8M | 12% |
| Commercial Operations | $49.0M | 6% |
| Commercial Operations Segment | $33.7M | 4% |
| Transferred At Point In Time | $1.3M | 0% |
ONC
Segment breakdown not available.
